Questions and answers in the management of primary central nervous system and ocular lymphomas

Haematologica

Volumn 88, Issue 9, 2003, Pages 1063-1068

  Ferreri, Andrés J M ^a   Dell'Oro, Stefania ^a   Reni, Michele ^a   Foppoli, Marco ^a   Anzalone, Nicoletta ^a   Govi, Silvia ^a   Picozzi, Piero ^a   Truci, Giulio ^a   Ponzoni, Maurilio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; METHOTREXATE; STEROID; THIOTEPA;

BLOOD BRAIN BARRIER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; DRUG DISTRIBUTION; DRUG MEGADOSE; EYE CANCER; HUMAN; MENINGITIS; NEUROTOXICITY; NOTE; PRACTICE GUIDELINE; PROGNOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; EYE NEOPLASMS; HUMANS; LYMPHOMA;

EID: 0141478872     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (67)

1. CBTRUS. Statistical report: Primary brain tumors in the United States, 1992-1997. Published by the CBTRUS, 2000.
2. Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513-20.
3. Deangelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990;40:80-6.
4. Soussain C, Merle-Beral H, Reux I, Sutton L, Fardeau C, Gerber S, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma 1996;23:339-45.
5. Akpek EK, Ahmed I, Hochberg FH, Soheilian M, Dryja TP, Jakobiec FA, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999;106:1805-10.
6. Rockwood EJ, Zakov ZN, Bay JW. Combined malignant lymphoma of the eye and CNS (reticulum-cell sarcoma). Report of three cases. J Neurosurg 1984;61:369-74.
7. Qualman SJ, Mendelsohn G, Mann RB, Green WR. Intraocular lymphomas. Natural history based on a clinicopathologic study of eight cases and review of the literature. Cancer 1983;52:878-86.
8. Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer 1996;77:827-33.
9. O'Neill BP, Illig JJ. Primary central nervous system lymphoma. Mayo Clin Proc 1989;64:1005-20.
10. Verbraeken HE, Hanssens M, Priem H, Lafaut BA, De Laey JJ. Ocular non-Hodgkin's lymphoma: a clinical study of nine cases. Br J Ophthalmol 1997;81:31-6.
11. O'Neill BP, Dinapoli RP, Kurtin PJ, Habermann TM. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J Neurooncol 1995;25:67-71.
12. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999;43:241-7.
13. Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997;8:227-34.
14. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000;11:927-37.
15. Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell'Oro S, Biron P, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 2001;51:419-25.
16. Deangelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-8.
17. Abrey LE, Deangelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-63.
18. O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000;18:519-26.
19. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
20. Laperriere NJ, Cerezo L, Milosevic MF, Wong CS, Patterson B, Panzarella T. Primary lymphoma of brain: results of management of a modern cohort with radiation therapy. Radiother Oncol 1997;43:247-52.
21. Hoang-Xuan K, Delattre JY. Ongoing protocols for non-AIDS primary central nervous system lymphoma. J Neurooncol 1999;43:287-91.
22. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-95.
23. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996;46:1757-9.
24. O'Brien PC, Roos DE, Liew KH, Trotter GE, Barton MB, Walker QJ, et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med J Aus 1996;165:424-7.
25. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259-68.
26. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-71.
27. Mead GM, Bleehen NM, Gregor A, Builimore J, Shirley D, Rampling RP, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000;89:1359-70.
28. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995;33:663-73.
29. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996;14:556-64.
30. Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. Cancer Res 1988;48:694-701.
31. Bessell EM, Lopez-Guillermo A, Villa S, Verger E, Nomdedeu B, Petit J, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002;20:231-6.
32. Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 1996;30:257-65.
33. Dent S, Eapen L, Girard A, Hugenholtz H, DaSilva V, Stewart DJ. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. J Neurooncol 1996;28:25-30.
34. Ng S, Rosenthal MA, Ashley D, Cher L High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro-oncol 2000;2:40-4.
35. Hiraga S, Arita N, Ohnishi T, Kohmura E, Yamamoto K, Oku Y, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999;91:221-30.
36. Balmaceda C, Gaynor JJ, Sun M, Gluck JT, Deangelis LM. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 1995;38:202-9.
37. Bessell EM, Graus F, Punt JA, Firth JL, Hope DT, Moloney AJ, et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996;14:945-54.
38. Ferreri AJ, Reni M, Dell'Oro S, Ciceri F, Bernardi M, Camba L, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 2001;60:134-40.
39. Khan RB, Shi W, Thaler HT, Deangelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002;58:175-8.
40. Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998;16:3000-6.
41. Freilich RJ, Delattre JY, Monjour A, Deangelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996;46:435-9.
42. Abrey LE, Yahalom J, Deangelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144-50.
43. Char DH, Ljung BM, Deschenes J, Miller TR. Intraocular lymphoma: immunological and cytological analysis. Br J Ophthalmol 1988;72:905-11.
44. Freeman LN, Schachat AP, Knox DL, Michels RG, Green WR. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology 1987;94:1631-9.
45. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-104.
46. Whitcup SM, de Smet MD, Rubin BI, Palestine AG, Martin DF, Burnier M Jr, et al. Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 1993;100:1399-406.
47. Henson JW, Yang J, Batchelor T. Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol 1999;17:1329.
48. Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 2002;13:531-8.
49. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-6.
50. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-16.
51. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637-47.
52. Kraemer DF, Fortin D, Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and future directions. Curr Neurol Neurosci Rep 2002;2:216-24.
53. Tyson RM, Siegal T, Doolittle ND, Lacy C, Kraemer DF, Neuwelt EA. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma (in press).
54. Abrey L, Moskowitz C, Mason W. A phase II study of intensive methotrexate and cytarabine followed by high dose beam chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). Proc Am Soc Clin Oncol 2001;20:53 [abstract].
55. Illerhaus G, Marks R, Derigs G. High-dose-chemotherapy with autologous PBSCT and hyperfractionated radiotherapy as first-line treatment for primary CNS lymphoma (PCNSL). Update of a multicenter phase II Study. Onkologie 2001;54:14[abstract].
56. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742-9.
57. Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989;63:939-47.
58. Deangelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43.
59. Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer 1999;79:530-4.
60. Boiardi A, Silvani A, Pozzi A, Fariselli L, Broggi G, Salmaggi A. Chemotherapy is effective as early treatment for primary central nervous system lymphoma. J Neurol 1999;246:31-7.
61. Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 1996;18:1021-3.
62. Varadi G, Or R, Kapelushnik J, Naparstek E, Nagler A, Brautbar C, et al. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 1999;34:185-90.
63. Lawler BE, Betensky R, Hochberg F, Batchelor TT. Primary central nervous system lymphoma: the MGH experience 1987-2001. Proc Am Soc Clin Oncol 2002;21:75a [abstract].
64. Blay JY, Lasset C, Carrie C, Chauvin F, Coiffier B, Gisselbrecht C, et al. Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. Br J Cancer 1993;67:1136-41.
65. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-72.
66. Ponzoni M, Berger F, Chassagne C, Tinguely M, Jouvet A. Reactive perivascular T-cell infiltrate is an independent favorable prognostic factor in primary central nervous system lymphomas (PCNSL) in immunocompetent patients. Ann Oncol 2002;13:264[abstract].
67. Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063-9